Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24468435 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1HDAC6HTTCNR2 | |
| SCHEMBL24468432 | 0.73 | HTT (0.46) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL30841986 | 0.72 | MEN1 (0.38) | HTTRECQLMEN1KMT2A | |
| SCHEMBL24468422 | 0.72 | MEN1 (0.38) | HTTRECQLMEN1KMT2A | |
| SCHEMBL16887774 | 0.72 | ALDH1A1 (0.48) | KDM4EALDH1A1HDAC6HTTCNR2 | |
| SCHEMBL14190878 | 0.70 | HTT (0.45) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4266171 | 0.70 | HTT (0.53) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24468881 | 0.69 | SMN1; SMN2 (0.44) | ALDH1A1HTTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15008754 | 0.69 | ACHE (0.52) | KDM4EALDH1A1HDAC6HTTCNR2 | |
| SCHEMBL15029124 | 0.69 | ACHE (0.52) | KDM4EALDH1A1HDAC6HTTCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KDM4E 34/4885ALDH1A1 2101/4885HDAC6 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.